Ziftomenib in relapsed/refractory (R/R) NPM1 -mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study.

A new R.E.P.O dev log is upon us, which means Semiwork has a brand-new feature to show off, plus reminders about beta branch access and more!

Our lead drug candidate – RLS-1496, a potential first-in-class disease-altering GPX4 modulator – is currently in Phase I clinical trials. The Rubedo leadership team is composed of industry leaders and ...

This paper presents a two-phase cooling method using the R134a refrigerant to dissipate the heat energy (loss) generated by power electronics (PEs), such as those associated with rectifiers, ...

Is your car's A/C starting to fail? Keep your cool thanks to this list of the best car ACrefrigerant recharge bottles courtesy of Advance Auto Parts.

A phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed (ND) or pts with relapsed/refractory (R/R) acute myeloid leukemia (AML), or ...

Incorporating a phase-change material into concrete, researchers have created a self-heating material that can melt snow and ice for up to 10 hours without using salt or shovels. The novel ...

The increasing concerns of the global warming impact of traditional refrigerants (R-410a, R-245fa, R-134a, R-404a, etc.) drive the requirement for substitutes more compelling. Due to the remarkable ...